$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

$ctxr Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000121390022082217 Filed on December 22, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.804M	$3.692M	$15.66M
YoY Change	0.08%	26.93%	38.69%
% of Gross Profit
Research & Development	$3.446M	$3.857M	$17.66M
YoY Change	-36.87%	68.13%	44.24%
% of Gross Profit
Depreciation & Amortization	$730.00	$730.00	$2.923K
YoY Change	0.0%	0.0%	96.17%
% of Gross Profit
Operating Expenses	$7.250M	$7.550M	$33.32M
YoY Change	-21.7%	45.09%	41.58%
Operating Profit	-$7.250M		-$33.32M
YoY Change	-21.7%		41.58%
Interest Expense	$214.6K	$134.8K
YoY Change	531.4%	78.35%
% of Operating Profit
Other Income/Expense, Net	$3.800M	$0.00	$0.00
YoY Change			-100.0%
Pretax Income	-$3.450M	-$7.415M	-$33.06M
YoY Change	-62.61%	49.46%	43.42%
Income Tax	$144.0K	$576.0K	$576.0K
% Of Pretax Income
Net Earnings	-$3.594M	-$7.991M	-$33.64M
YoY Change	-61.05%	61.07%	45.92%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.02		-$0.23
Diluted Earnings Per Share	-$0.02	-$54.68K	-$0.23
COMMON SHARES
Basic Shares Outstanding	146.2M shares	146.1M shares	146.1M shares
Diluted Shares Outstanding	146.2M shares		146.1M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.89M	$41.71M	$41.71M
YoY Change	-43.62%	-40.47%	-40.47%
Cash & Equivalents	$36.89M	$41.71M	$41.71M
Short-Term Investments
Other Short-Term Assets	$5.430M	$2.853M	$2.853M
YoY Change	115.18%	4.06%	4.06%
Inventory
Prepaid Expenses	$5.430M	$2.853M
Receivables
Other Receivables
Total Short-Term Assets	$42.32M	$44.56M	$44.56M
YoY Change	-37.72%	-38.8%	-38.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.370K	$4.100K	$650.2K
YoY Change	-99.57%	-41.62%	-21.65%
Goodwill	$9.347M	$9.347M
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$38.06K	$38.06K	$38.06K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$69.39M	$69.44M	$69.44M
YoY Change	-0.26%	-0.26%	-0.26%
TOTAL ASSETS
Total Short-Term Assets	$42.32M	$44.56M	$44.56M
Total Long-Term Assets	$69.39M	$69.44M	$69.44M
Total Assets	$111.7M	$114.0M	$114.0M
YoY Change	-18.77%	-19.96%	-19.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.538M	$1.165M	$1.165M
YoY Change	-14.06%	-8.75%	-8.75%
Accrued Expenses	$690.4K	$1.405M	$3.365M
YoY Change	-87.57%	125.96%	24.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.537M	$4.530M	$4.530M
YoY Change	-38.2%	13.75%	13.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$428.6K	$481.3K	$481.3K
YoY Change	-32.05%	-29.04%	-29.04%
Total Long-Term Liabilities	$428.6K	$481.3K	$481.3K
YoY Change	-32.05%	-29.04%	-29.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.537M	$4.530M	$4.530M
Total Long-Term Liabilities	$428.6K	$481.3K	$481.3K
Total Liabilities	$10.67M	$10.57M	$11.17M
YoY Change	-21.29%	9.61%	9.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$133.3M	-$129.7M
YoY Change		35.02%
Common Stock	$146.2K	$146.2K
YoY Change		0.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$100.4M	$102.8M	$102.8M
YoY Change
Total Liabilities & Shareholders Equity	$111.7M	$114.0M	$114.0M
YoY Change	-18.77%	-19.96%	-19.96%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022
OPERATING ACTIVITIES
Net Income	-$3.594M	-$7.991M	-$33.64M
YoY Change	-61.05%	61.07%	45.92%
Depreciation, Depletion And Amortization	$730.00	$730.00	$2.923K
YoY Change	0.0%	0.0%	96.17%
Cash From Operating Activities	-$4.824M	-$6.333M	-$28.36M
YoY Change	3.72%	13.26%	16.95%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-$4.824M	-6.333M	-$28.36M
Cash From Investing Activities		0.000
Cash From Financing Activities		0.000
Net Change In Cash	-$4.824M	-6.333M	-$28.36M
YoY Change		-86.11%	-150.45%
FREE CASH FLOW
Cash From Operating Activities	-$4.824M	-$6.333M	-$28.36M
Capital Expenditures		$0.00
Free Cash Flow		-$6.333M	-$28.36M
YoY Change		-118.4%	-280.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3425913
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Commerce Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	First Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranford
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07016
CY2022	dei	City Area Code CityAreaCode	(908)
CY2022	dei	Local Phone Number LocalPhoneNumber	967-6677
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38174
CY2022	dei	Entity Registrant Name EntityRegistrantName	Citius Pharmaceuticals, Inc.
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	CTXR
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Public Float EntityPublicFloat	240000000	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	146211130	shares
CY2022	dei	Auditor Firm AuditorFirmId	392
CY2022	dei	Auditor Name AuditorName	Wolf & Company, P.C.
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41711690	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70072946	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2852580	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2741404	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	44564270	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	72814350	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4100	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7023	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646074	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	822828	usd
CY2022Q3	us-gaap	Deposits Assets DepositsAssets	38062	usd
CY2021Q3	us-gaap	Deposits Assets DepositsAssets	38062	usd
CY2022Q3	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2021Q3	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	9346796	usd
CY2021Q3	us-gaap	Goodwill Goodwill	9346796	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	68784858	usd
CY2021Q3	us-gaap	Other Assets OtherAssets	68784858	usd
CY2022Q3	us-gaap	Assets Assets	113999302	usd
CY2021Q3	us-gaap	Assets Assets	142429059	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1165378	usd
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1277095	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1405394	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	621960	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1762251	usd
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1906000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196989	usd
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	177237	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4530012	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3982292	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5561800	usd
CY2021Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4985800	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	481245	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	678234	usd
CY2022Q3	us-gaap	Liabilities Liabilities	10573057	usd
CY2021Q3	us-gaap	Liabilities Liabilities	9646326	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	146211130	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	146211130	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145979429	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	145979429	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	146211	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	145979	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	232368121	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	228084195	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129688467	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96047821	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	102825865	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	132182353	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2021Q3	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103426245	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	132782733	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113999302	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	142429059	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17655482	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12240503	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11754609	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9836412	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3905954	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1454979	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	33316045	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	23531894	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-33316045	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-23531894	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	251399	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	261825	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	166557	usd
CY2021	us-gaap	Other Income OtherIncome	59917	usd
CY2021	us-gaap	Interest Expense InterestExpense	10839	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	251399	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	477460	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33064646	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23054434	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	576000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33640646	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-23054434	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1450876	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33640646	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24505310	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146082399	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108599080	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33670668	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	500	usd
CY2021	ctxr	Issuance Of Common Stock In Private Placement Offering Net Of Costs IssuanceOfCommonStockInPrivatePlacementOfferingNetOfCosts	1549602	usd
CY2021	ctxr	Proceeds From Issuance Of Private Placements ProceedsFromIssuanceOfPrivatePlacements	18450410	usd
CY2021	ctxr	Issuance Of Common Stock In Registered Direct Offering Net Of Costs IssuanceOfCommonStockInRegisteredDirectOfferingNetOfCosts	5520160	usd
CY2021	ctxr	Issuance Of Common Stock In Registered Direct Offering IssuanceOfCommonStockInRegisteredDirectOffering	70979842	usd
CY2021	ctxr	Issuance Of Common Stock Upon Exercise Of Warrants IssuanceOfCommonStockUponExerciseOfWarrants	31130134	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	68000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	82634	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1454979	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-23054434	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	132782733	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	378204	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3905954	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-33640646	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103426245	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33640646	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-23054434	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3905954	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1454979	usd
CY2022	ctxr	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	378204	usd
CY2021	ctxr	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	68000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	176754	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	163376	usd
CY2022	us-gaap	Depreciation Depreciation	2923	usd
CY2021	us-gaap	Depreciation Depreciation	1492	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	576000	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	166557	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	111176	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2619167	usd
CY2021	ctxr	Increase Decrease In Other Deposit IncreaseDecreaseInOtherDeposit	19031	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-111717	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-579140	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	783434	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	457920	usd
CY2022	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-143749	usd
CY2021	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	251081	usd
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	87996	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-177237	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-158999	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28361256	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24250414	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6938	usd
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	40000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40006938	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	172970	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	500	usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	31130134	usd
CY2021	ctxr	Proceeds From Common Stock Option Exercises ProceedsFromCommonStockOptionExercises	82634	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	18450410	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	70979842	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120470550	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-28361256	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	56213198	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70072946	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13859748	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41711690	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70072946	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Business</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Pharmaceuticals, Inc. (“Citius,” the “Company” or “we”) is a late-stage biopharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products and stem cell therapies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 30, 2016, Citius acquired Leonard-Meron Biosciences, Inc. (“LMB”) as a wholly-owned subsidiary. The Company acquired all the outstanding stock of LMB by issuing shares of its common stock. The net assets acquired included identifiable intangible assets of $19,400,000 related to in-process research and development. The Company recorded goodwill of $9,346,796 for the excess of the purchase price over the net assets acquired.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 11, 2020, we formed NoveCite, Inc. (“NoveCite”), a Delaware corporation, of which we own 75% of the issued and outstanding capital stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 23, 2021, we formed Citius Acquisition Corp. (“Citius Acq.”), a wholly-owned subsidiary in conjunction with the acquisition of I/ONTAK, which began operations in April 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In-process research and development (“IPR&D) consists of i) $19,400,000 acquisition value of LMB’s leading drug candidate (Mino-Lok), which is an antibiotic solution used to treat catheter-related bloodstream infections and is expected to be amortized on a straight-line basis over a period of eight years commencing upon revenue generation, and ii) $40,000,000 acquisition value of the exclusive license for E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma and is expected to be amortized on a straight-line basis over a period of twelve years commencing upon revenue generation. Goodwill of $9,346,796 represents the value of LMB’s industry relationships and its assembled workforce. Goodwill will not be amortized but will be tested at least annually for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since its inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. Citius is subject to a number of risks common to companies in the pharmaceutical industry including, but not limited to, risks related to the development by Citius or its competitors of research and development stage products, market acceptance of its products, competition from larger companies, dependence on key personnel, dependence on key suppliers and strategic partners, the Company’s ability to obtain additional financing and the Company’s compliance with governmental and other regulations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the operations of Citius Pharmaceuticals, Inc., and its wholly-owned subsidiaries, Citius Pharmaceuticals, LLC, LMB and Citius Acq., and its majority-owned subsidiary NoveCite. NoveCite, was inactive until October 2020. Citius Acq. began operations in April 2022. All significant inter-company balances and transactions have been eliminated in consolidation.</p>
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	19400000	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	40000000	usd
CY2022Q3	us-gaap	Goodwill Gross GoodwillGross	9346796	usd
CY2022	ctxr	Negative Cash Flow Operations NegativeCashFlowOperations	28361256	usd
CY2021	ctxr	Negative Cash Flow Operations NegativeCashFlowOperations	24250414	usd
CY2022Q3	ctxr	Working Capital WorkingCapital	40	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	90000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	90000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	100000	usd
CY2022	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	25000	usd
CY2022	ctxr	Maximum Aggregate Annual Royalties MaximumAggregateAnnualRoyalties	150000	usd
CY2022	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	1100000	usd
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	125000	usd
CY2022Q1	ctxr	Annual Maintenance Fee AnnualMaintenanceFee	60000	usd
CY2021Q1	ctxr	Annual Maintenance Fee AnnualMaintenanceFee	45000	usd
CY2022	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2034-01-02
CY2020Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	100000	usd
CY2022	ctxr	Developmental Milestone Description DevelopmentalMilestoneDescription	NoveCite is obligated to pay Novellus up to $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Novellus an amount equal to a mid-twenties percentage of any sublicensee fees it receives.
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.50	pure
CY2022Q3	ctxr	Operating Lease Future Minimum Payments Due In Three Years OperatingLeaseFutureMinimumPaymentsDueInThreeYears	253883	usd
CY2022Q3	ctxr	Operating Lease Future Minimum Payments Due In Four Years OperatingLeaseFutureMinimumPaymentsDueInFourYears	21460	usd
CY2022	us-gaap	Debt Instrument Description Of Variable Rate Basis DebtInstrumentDescriptionOfVariableRateBasis	Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a BLA for I/ONTAK.
CY2022	ctxr	Description Of License Agreement DescriptionOfLicenseAgreement	The term of the license agreement will continue until (i) if there has not been a commercial sale of a licensed product in the territory, until the 10-year anniversary of the original license effective date, March 30, 2016, or (ii) if there has been a first commercial sale of a licensed product in the territory within the 10-year anniversary of the original license effective date, the 10-year anniversary of the first commercial sale on a country-by-country basis. The term of the license may be extended for additional 10-year periods for all countries in the territory by notifying Eisai and paying an extension fee equal to $10 million.
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3589392	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development and goodwill impairment, stock-based compensation, valuation of warrants, and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	19400000	usd
CY2022	ctxr	Amortized Straight Line Basis Over Period AmortizedStraightLineBasisOverPeriod	P8Y
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	40000000	usd
CY2022	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P20Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3645000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.97
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9400171	shares
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3	ctxr	Operating Lease Future Minimum Payments Due OperatingLeaseFutureMinimumPaymentsDue	768532	usd
CY2022	us-gaap	Debt Instrument Description DebtInstrumentDescription	Notes with an aggregate principal balance of $104,000 accrued interest at the prime rate plus 1.0% per annum and notes with an aggregate principal balance of $68,970 accrued interest at 12% per annum.
CY2021Q2	us-gaap	Notes Payable NotesPayable	172970	usd
CY2021Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	38917	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	59917	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	9606	usd
CY2020Q2	ctxr	Paycheck Protection Program Description PaycheckProtectionProgramDescription	On April 12, 2020, due to the business disruption caused by the COVID-19 health crisis, the Company applied for a forgivable loan through the Small Business Association’s Paycheck Protection Program (the “PPP”). In accordance with the provisions of the PPP, the loan accrued interest at a rate of 1% and a portion of the loan may be forgiven if it is used to pay qualifying costs such as payroll, rent and utilities. Amounts that are not forgiven will be repaid two years from the date of the loan. On April 15, 2020, the Company received $164,583 from the PPP through its bank.
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	1233	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	166557	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	50000	shares
CY2021Q1	us-gaap	Stock Issued1 StockIssued1	68000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	50201	shares
CY2021Q4	us-gaap	Stock Issued1 StockIssued1	95884	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	100000	shares
CY2022Q1	us-gaap	Stock Issued1 StockIssued1	178000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	81500	shares
CY2022Q3	us-gaap	Stock Issued1 StockIssued1	104320	usd
CY2021Q1	ctxr	Common Stock Offerings Description CommonStockOfferingsDescription	On January 27, 2021, the Company closed a private placement for 15,455,960 common shares and warrants to purchase 7,727,980 common shares, at a purchase price of $1.294 per common share and accompanying warrant, for gross proceeds of $20,000,012. The 7,727,980 warrants are immediately exercisable at $1.231 per common share for a term of five and one-half years. The Company paid the placement agent a fee of 7% of the gross proceeds totaling $1,400,001 and issued the placement agent 1,081,917 immediately exercisable warrants at $1.6175 per common share for a term of five and one-half years. The Company also reimbursed the placement agent for $85,000 in expenses and incurred $64,601 in other expenses. Net proceeds from the offering were $18,450,410. The estimated fair value of the 7,727,980 warrants issued to the investors was approximately $7,582,000 and the estimated fair value of the 1,081,917 warrants issued to the placement agent was approximately $1,025,000.
CY2022Q3	ctxr	Option To Purchase Share Outstanding OptionToPurchaseShareOutstanding	4855000	shares
CY2022	ctxr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P10Y
CY2022Q3	ctxr	Less Interest LessInterest	90298	usd
CY2022Q3	ctxr	Present Value Of Lease Liabilities PresentValueOfLeaseLiabilities	678234	usd
CY2022	ctxr	Schedule Operating Leases Assets And Liabilities ScheduleOperatingLeasesAssetsAndLiabilities	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Leases</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Assets</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Lease asset</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 11%; text-align: center; padding-bottom: 1.5pt">Operating</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">646,074</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">822,828</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total lease assets</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">646,074</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">822,828</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Liabilities</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Current</td><td> </td> <td style="text-align: center">Operating</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">196,989</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">177,237</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Non-current</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">481,245</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">678,234</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">678,234</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">855,471</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5755171	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.13
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.07
CY2022	ctxr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M21D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	869509	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4140116	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.42
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M29D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	595405	usd
CY2021Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.34
CY2021	ctxr	Stock Options Vest Over Terms StockOptionsVestOverTerms	P10Y
CY2022	ctxr	Share Issued Price Per Share ShareIssuedPricePerShare	1.67
CY2022	ctxr	Stock Options Vest Over Terms StockOptionsVestOverTerms	P10Y
CY2022	ctxr	Stockbased Compensation Expense Description StockbasedCompensationExpenseDescription	Stock-based compensation expense for the years ended September 30, 2022 and 2021 was $3,905,954 (including $133,332 for the NoveCite Stock Plan) and $1,454,979 (including $83,555 for the NoveCite Stock Plan), respectively.
CY2022Q3	ctxr	Citius Stock Plans CitiusStockPlans	5317681	usd
CY2022	ctxr	Weighted Average Period Term WeightedAveragePeriodTerm	P1Y11M1D
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2000000	shares
CY2022	ctxr	Common Shares Outstanding CommonSharesOutstanding	2000000	shares
CY2021	ctxr	Stock Option Plans Description StockOptionPlansDescription	the year ended September 30, 2021, NoveCite granted options to purchase 2,000,000 common shares to employees at a weighted average exercise price of $0.24 per share, of which 1,084,444 are exercisable as of September 30, 2022. The weighted average grant date fair value of the options granted during the year ended September 30, 2021 was estimated at $0.20 per share. All these options vest over 36 months and have a term of 10 years. The weighted average remaining contractual term of options outstanding under the NoveCite Stock Plan is 8.39 years. At September 30, 2022, unrecognized total compensation cost related to unvested awards under the NoveCite Stock Plan of $183,111 is expected to be recognized over a weighted average period of 1.45 years.
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	38325489	shares
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646074	usd
CY2022Q3	ctxr	Number Of Warrants Issued NumberOfWarrantsIssued	38325489	shares
CY2021Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2021Q2	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	1294498	usd
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.42
CY2021	us-gaap	Dividends Common Stock Paidinkind DividendsCommonStockPaidinkind	1450876	usd
CY2021Q3	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	31130134	usd
CY2022Q3	ctxr	Operating Lease Future Minimum Payments Due Current OperatingLeaseFutureMinimumPaymentsDueCurrent	244165	usd
CY2022Q3	ctxr	Operating Lease Future Minimum Payments Due In Two Years OperatingLeaseFutureMinimumPaymentsDueInTwoYears	249024	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	822828	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease	9400171	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	3885000	shares
CY2022	ctxr	Warrants Warrants	38325489	shares
CY2022	ctxr	Common Stock Reserved CommonStockReserved	51610660	shares
CY2020Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	500000	shares
CY2022	ctxr	Schedule Lease Expense ScheduleLeaseExpense	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Lease cost</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>Year Ended<br/> September 30,<br/> 2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> September 30,<br/> 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">238,822</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">238,824</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Variable lease cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">772</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">194</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Total lease cost</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">239,594</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">239,018</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Other information</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted-average remaining lease term - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">3.1 Years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">4.1 Years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted-average discount rate - operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8.0</td><td style="width: 1%; text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	238822	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	238824	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	772	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	194	usd
CY2022	us-gaap	Lease Cost LeaseCost	239594	usd
CY2021	us-gaap	Lease Cost LeaseCost	239018	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q3	ctxr	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	646074	usd
CY2021Q3	ctxr	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	822828	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196989	usd
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	177237	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	481245	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	678234	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	678234	usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	855471	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	62068	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	75448	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	576000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.063	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.063	pure
CY2022	ctxr	Permanent Differences Percentage PermanentDifferencesPercentage	0.018	pure
CY2021	ctxr	Permanent Differences Percentage PermanentDifferencesPercentage	0.007	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.272	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.266	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.017	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34673000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25508000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1569000	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1105000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3689000	usd
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2564000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	39931000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29177000	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	5561800	usd
CY2021Q3	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	4985800	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5561800	usd
CY2021Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4985800	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5561800	usd
CY2021Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4985800	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10754000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12257000	usd
CY2022	ctxr	Federal Net Operating Loss Carryforward FederalNetOperatingLossCarryforward	121000000	usd
CY2022	ctxr	Carryforwards Amount CarryforwardsAmount	86000000	usd
CY2022	ctxr	Federal Research And Development FederalResearchAndDevelopment	3208000	usd
CY2022	us-gaap	Other Income OtherIncome		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2022	ctxr	Increase Decrease In Other Deposit IncreaseDecreaseInOtherDeposit		usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2022	ctxr	Proceeds From Common Stock Option Exercises ProceedsFromCommonStockOptionExercises		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions		usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross		usd
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001506251

Files In Submission

Name	View Source	Status
0001213900-22-082217-index-headers.html	Edgar Link	pending
0001213900-22-082217-index.html	Edgar Link	pending
0001213900-22-082217.txt	Edgar Link	pending
0001213900-22-082217-xbrl.zip	Edgar Link	pending
ctxr-20220930.xsd	Edgar Link	pending
f10k2022ex23-1_citiuspharma.htm	Edgar Link	pending
f10k2022ex31-1_citiuspharma.htm	Edgar Link	pending
f10k2022ex31-2_citiuspharma.htm	Edgar Link	pending
f10k2022ex32-1_citiuspharma.htm	Edgar Link	pending
f10k2022ex4-25_citiuspharma.htm	Edgar Link	pending
f10k2022_citiuspharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
ctxr-20220930_def.xml	Edgar Link	unprocessable
ctxr-20220930_pre.xml	Edgar Link	unprocessable
ctxr-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ctxr-20220930_cal.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
f10k2022_citiuspharma_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

2022 Q4 Form 10-K Financial Statement

#000121390022082217 Filed on December 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR Citius Pharmaceuticals, Inc. Stock $ctxr

2022 Q4 Form 10-K Financial Statement

#000121390022082217 Filed on December 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr